GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (STU:LX31) » Definitions » EV-to-FCF

Lexicon Pharmaceuticals (STU:LX31) EV-to-FCF : -2.05 (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is Lexicon Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lexicon Pharmaceuticals's Enterprise Value is €351.99 Mil. Lexicon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-171.46 Mil. Therefore, Lexicon Pharmaceuticals's EV-to-FCF for today is -2.05.

The historical rank and industry rank for Lexicon Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:LX31' s EV-to-FCF Range Over the Past 10 Years
Min: -15.81   Med: -4.52   Max: 12.07
Current: -2.06

During the past 13 years, the highest EV-to-FCF of Lexicon Pharmaceuticals was 12.07. The lowest was -15.81. And the median was -4.52.

STU:LX31's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 8.405 vs STU:LX31: -2.06

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-09), Lexicon Pharmaceuticals's stock price is €4.096. Lexicon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.767. Therefore, Lexicon Pharmaceuticals's PE Ratio for today is At Loss.


Lexicon Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Lexicon Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals EV-to-FCF Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.65 -2.41 -5.69 -3.08 -1.91

Lexicon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.16 -3.65 -1.15 -1.91 -1.84

Competitive Comparison of Lexicon Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Lexicon Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's EV-to-FCF falls into.



Lexicon Pharmaceuticals EV-to-FCF Calculation

Lexicon Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=351.989/-171.458
=-2.05

Lexicon Pharmaceuticals's current Enterprise Value is €351.99 Mil.
Lexicon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-171.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexicon Pharmaceuticals  (STU:LX31) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lexicon Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.096/-0.767
=At Loss

Lexicon Pharmaceuticals's share price for today is €4.096.
Lexicon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.767.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Lexicon Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (STU:LX31) Business Description

Traded in Other Exchanges
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals (STU:LX31) Headlines

No Headlines